Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,236 shares of the medical equipment provider’s stock after selling 4,100 shares during the quarter. Stanley Laman Group Ltd. owned approximately 0.09% of Lantheus worth $5,478,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the 3rd quarter valued at $25,000. Signaturefd LLC increased its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. GAMMA Investing LLC boosted its stake in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares during the last quarter. Finally, World Investment Advisors LLC bought a new position in shares of Lantheus during the third quarter worth $60,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LNTH shares. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, Truist Financial reaffirmed a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $131.86.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $82.10 on Thursday. The business has a fifty day moving average price of $91.76 and a 200 day moving average price of $98.13. The company has a market cap of $5.71 billion, a P/E ratio of 13.66 and a beta of 0.44. Lantheus Holdings, Inc. has a one year low of $54.69 and a one year high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.